Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05787002
Other study ID # D7960C00002
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date March 9, 2023
Est. completion date May 15, 2023

Study information

Verified date May 2023
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to assess the effect of AZD0780 on the pharmacokinetics of rosuvastatin, and to assess the safety and tolerability of AZD0780 single dose, in healthy participants administered alone and in combination with rosuvastatin.


Description:

Eligible participants will be randomized, in a 1:1 ratio into 2 of the treatment arms. Each participant will receive 2 treatments in total throughout the study. The following treatments will be given in randomized order in fasting state: Treatment A: single dose of rosuvastatin tablet alone Treatment B: single dose of rosuvastatin tablet + AZD0780 tablet The study will comprise: 1. A Screening Period of maximum 28 days. 2. Two Treatment Periods up to 3 days 3. A follow-up period of 10 to 12 days after the last administration of the study drug. Following an overnight fast (minimum 10 hours) participants will receive either of the two treatments and will remain resident in the Clinical Unit until up to 48 hours after dosing of the study drug (up to Day 3). The total duration of the study will be up to 9 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date May 15, 2023
Est. primary completion date May 15, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Provision of signed and dated, written informed consent prior to any study specific procedures. - Healthy male and female participants (of non-childbearing potential) aged 18 to 60 years, inclusive, with suitable veins for cannulation or repeated venipuncture. - Females must have a negative pregnancy test at screening and must not be lactating - Participants with BMI between 18 and 30 kg/m^2, inclusive, and weighing between 50 kg and 100 kg, inclusive Exclusion Criteria: - History or presence of gastrointestinal, hepatic or renal disease, or any other clinically significant disease or disorder - Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody, or HIV. - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first vaccination within 30 days prior to randomization and second vaccination within 10 days of screening - Confirmed Coronavirus disease 2019 (COVID-19) infection at admission, by Polymerase chain reaction (PCR) test - Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening - History or presence of severe allergy/hypersensitivity - Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the 3 months prior to screening - Positive screen for drugs of abuse, alcohol, or cotinine at screening - Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of the study drug - Any clinically significant abnormalities in clinical chemistry, hematology, coagulation, urinalysis results, ECG or vital signs

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AZD0780
AZD0780 will be administered orally as a single dose after an overnight fast of at least 10 hours with approximately 240 mL of water.
Rosuvastatin
Rosuvastatin will be administered orally as a single dose after an overnight fast of at least 10 hours with approximately 240 mL of water.

Locations

Country Name City State
United States Research Site Brooklyn Maryland

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area under plasma concentration-time curve from 0 to infinity (AUCinf) of Rosuvastatin The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed. Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose
Primary Area under the plasma concentration-curve from 0 to the last quantifiable concentration (AUClast) of Rosuvastatin The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed. Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose
Primary Maximum observed plasma concentration (Cmax) of Rosuvastatin The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed. Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose
Primary Terminal elimination half-life (t½?z) of Rosuvastatin The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed. Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose
Primary Time to reach maximum observed concentration (tmax) of Rosuvastatin The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed. Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose
Primary Apparent total body clearance (CL/F) of Rosuvastatin The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed. Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose
Primary Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) of Rosuvastatin The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed. Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose
Primary Area under plasma concentration-time curve from 0 to infinity (AUCinf) of AZD0780 The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed. Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose
Primary Area under the plasma concentration-curve from 0 to the last quantifiable concentration (AUClast) of AZD0780 The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed. Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose
Primary Maximum observed plasma concentration (Cmax) of AZD0780 The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed. Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose
Primary Time to reach maximum observed concentration (tmax) of AZD0780 The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed. Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose
Primary Terminal elimination half-life (t½?z) of AZD0780 The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed. Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose
Primary Apparent total body clearance (CL/F) of AZD0780 The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed. Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose
Primary Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) of AZD0780 The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed. Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose
Secondary Number of participants with Adverse Events The safety and tolerability of AZD0780 in combination with rosuvastatin in healthy participants will be assessed. From Screening (= 28 days to Day -2) until Follow-up Visit (10 to 12 days post-final dose)
See also
  Status Clinical Trial Phase
Completed NCT00001154 - Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
Not yet recruiting NCT06405880 - Pharmacist Case Finding and Intervention for Vascular Prevention Trial N/A
Recruiting NCT02837367 - Use of Nutrigenomic Models for the Personalized Treatment With Medical Foods in Obese People N/A
Active, not recruiting NCT02223793 - Vascular Lifestyle-Intervention and Screening in Pharmacy N/A
Active, not recruiting NCT02600338 - Meta-analyses of the Effect of Legumes on Blood Pressure N/A
Completed NCT02163044 - The Hellenic Postprandial Lipemia Study (HPLS)
Recruiting NCT01972113 - Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study) N/A
Recruiting NCT01705873 - Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen N/A
Completed NCT01764295 - Clinical Study for Patients With Hypertension Associated With Dyslipidemia Phase 3
Completed NCT01531062 - Effect of Nigella Sativa on Lipid Profiles in Elderly Phase 2
Completed NCT01990391 - Brazil Nut Consumption in Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities N/A
Terminated NCT01414166 - Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108) Phase 3
Recruiting NCT01670968 - HIV Reverse Cholesterol Transport Study
Completed NCT00977288 - A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029) Phase 2
Completed NCT01285544 - The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia Phase 4
Completed NCT00768274 - Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol Phase 1/Phase 2
Withdrawn NCT00664287 - Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082) Phase 3
Completed NCT00300430 - Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia. Phase 3
Completed NCT01483235 - Reduced Cardiac Rehabilitation Program N/A
Completed NCT00312923 - Preliminary Study of Safety and Efficacy of Policosanol Phase 2